help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chapman, I. M.
Right arrow Articles by Thorner, M. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chapman, I. M.
Right arrow Articles by Thorner, M. O.

Journal of Clinical Endocrinology & Metabolism, Vol 81, 4249-4257, Copyright © 1996 by Endocrine Society

ARTICLES

Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects

IM Chapman, MA Bach, E Van Cauter, M Farmer, D Krupa, AM Taylor, LM Schilling, KY Cole, EH Skiles, SS Pezzoli, ML Hartman, JD Veldhuis, GJ Gormley and MO Thorner
Department of Medicine, University of Virginia Health Sciences Center, Charlottesville 22908, USA.

Aging is associated with declining activity of the GH axis, possibly contributing to adverse body composition changes and increased incidence of cardiovascular disease. The stimulatory effects on the GH- insulin-like growth factor I (IGF-I) axis of orally administered MK- 677, a GH-releasing peptide mimetic, were investigated. Thirty-two healthy subjects (15 women and 17 men, aged 64-81 yr) were enrolled in a randomized, double blind, placebo-controlled trial. They received placebo or 2, 10, or 25 mg MK-677, orally, once daily for 2 separate study periods of 14 and 28 days. At baseline and on day 14 of each study period, blood was collected every 20 min for 24 h to measure GH, PRL, and cortisol. Attributes of pulsatile GH release were assessed by 3 independent algorithms. MK-677 administration for 2 weeks increased GH concentrations in a dose-dependent manner, with 25 mg/day increasing mean 24-h GH concentration 97 +/- 23% (mean +/- SE; P < 0.05 vs. baseline). This increase was due to an enhancement of preexisting pulsatile GH secretion. GH pulse height and interpulse nadir concentrations increased significantly without significant changes in the number of pulses. With 25 mg/day MK-677 treatment, mean serum IGF-I concentrations increased into the normal range for young adults (141 +/- 21 microgram/L at baseline, 219 +/- 21 micrograms/L at 2 weeks, and 265 +/- 29 micrograms/L at 4 weeks; P < 0.05). MK-677 produced significant increases in fasting glucose (5.4 +/- 0.3 to 6.8 +/- 0.4 mmol/L at 4 weeks; P < 0.01 vs. baseline) and IGF-binding protein-3. Circulating cortisol concentrations did not change, and PRL concentrations increased 23%, but remained within the normal range. Once daily treatment of older people with oral MK-677 for up to 4 weeks enhanced pulsatile GH release, significantly increased serum GH and IGF-I concentrations, and, at a dose of 25 mg/day, restored serum IGF-I concentrations to those of young adults.


This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
H. Rafael
Rejuvenation in Older Adults Receiving Oral Ghrelin
Ann Intern Med, May 5, 2009; 150(9): 653 - 654.
[Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
G. Fanciulli, A. Delitala, and G. Delitala
Growth hormone, menopause and ageing: no definite evidence for 'rejuvenation' with growth hormone
Hum. Reprod. Update, May 1, 2009; 15(3): 341 - 358.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. K. White, C. D. Petrie, W. Landschulz, D. MacLean, A. Taylor, K. Lyles, J. Y. Wei, A. R. Hoffman, R. Salvatori, M. P. Ettinger, et al.
Effects of an Oral Growth Hormone Secretagogue in Older Adults
J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1198 - 1206.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. J. Sevigny, J. M. Ryan, C. H. van Dyck, Y. Peng, C. R. Lines, M. L. Nessly, and On behalf of the MK-677 Protocol 30 Study Group
Growth hormone secretagogue MK-677: No clinical effect on AD progression in a randomized trial
Neurology, November 18, 2008; 71(21): 1702 - 1708.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
R. Nass, S. S. Pezzoli, M. C. Oliveri, J. T. Patrie, F. E. Harrell Jr., J. L. Clasey, S. B. Heymsfield, M. A. Bach, M. L. Vance, and M. O. Thorner
Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized Trial
Ann Intern Med, November 4, 2008; 149(9): 601 - 611.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. D. Veldhuis, G. A. Reynolds, A. Iranmanesh, and C. Y. Bowers
Twenty-Four Hour Continuous Ghrelin Infusion Augments Physiologically Pulsatile, Nycthemeral, and Entropic (Feedback-Regulated) Modes of Growth Hormone Secretion
J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3597 - 3603.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
H. Ariyasu, H. Iwakura, G. Yamada, K. Nakao, K. Kangawa, and T. Akamizu
Efficacy of Ghrelin as a Therapeutic Approach for Age-Related Physiological Changes
Endocrinology, July 1, 2008; 149(7): 3722 - 3728.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Nass, L. S. Farhy, J. Liu, C. E. Prudom, M. L. Johnson, P. Veldhuis, S. S. Pezzoli, M. C. Oliveri, B. D. Gaylinn, H. M. Geysen, et al.
Evidence for Acyl-Ghrelin Modulation of Growth Hormone Release in the Fed State
J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1988 - 1994.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Y. Sun, N. F. Butte, J. M. Garcia, and R. G. Smith
Characterization of Adult Ghrelin and Ghrelin Receptor Knockout Mice under Positive and Negative Energy Balance
Endocrinology, February 1, 2008; 149(2): 843 - 850.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
W. P. Esler, J. Rudolph, T. H. Claus, W. Tang, N. Barucci, S.-E. Brown, W. Bullock, M. Daly, L. DeCarr, Y. Li, et al.
Small-Molecule Ghrelin Receptor Antagonists Improve Glucose Tolerance, Suppress Appetite, and Promote Weight Loss
Endocrinology, November 1, 2007; 148(11): 5175 - 5185.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. G.-S. Frutos, L. Cacicedo, C. Fernandez, D. Vicent, B. Velasco, H. Zapatero, and F. Sanchez-Franco
Insights into a role of GH secretagogues in reversing the age-related decline in the GH/IGF-I axis
Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1140 - E1152.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Y. Sun, J. M. Garcia, and R. G. Smith
Ghrelin and Growth Hormone Secretagogue Receptor Expression in Mice during Aging
Endocrinology, March 1, 2007; 148(3): 1323 - 1329.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. O. L. Jorgensen
A simple twist of science: the convoluted tale of ghrelin continues.
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3279 - 3280.
[Full Text] [PDF]

Home page
 EndocrinologyHome page
P. Zizzari, H. Halem, J. Taylor, J. Z. Dong, R. Datta, M. D. Culler, J. Epelbaum, and M. T. Bluet-Pajot
Endogenous Ghrelin Regulates Episodic Growth Hormone (GH) Secretion by Amplifying GH Pulse Amplitude: Evidence from Antagonism of the GH Secretagogue-R1a Receptor
Endocrinology, September 1, 2005; 146(9): 3836 - 3842.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
R. G. Smith
Development of Growth Hormone Secretagogues
Endocr. Rev., May 1, 2005; 26(3): 346 - 360.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
R. G. Smith, L. Betancourt, and Y. Sun
Molecular Endocrinology and Physiology of the Aging Central Nervous System
Endocr. Rev., April 1, 2005; 26(2): 203 - 250.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. Popovic, D. Miljic, S. Pekic, P. Pesko, M. Djurovic, M. Doknic, S. Damjanovic, D. Micic, G. Cvijovic, J. Glodic, et al.
Low Plasma Ghrelin Level in Gastrectomized Patients Is Accompanied by Enhanced Sensitivity to the Ghrelin-Induced Growth Hormone Release
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2187 - 2191.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Gauna, P. J. D. Delhanty, L. J. Hofland, J. A. M. J. L. Janssen, F. Broglio, R. J. M. Ross, E. Ghigo, and A. J. van der Lely
Ghrelin Stimulates, Whereas Des-Octanoyl Ghrelin Inhibits, Glucose Output by Primary Hepatocytes
J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1055 - 1060.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. J. Orrego, E. Dimaraki, K. Symons, and A. L. Barkan
Physiological Testosterone Replenishment in Healthy Elderly Men Does Not Normalize Pituitary Growth Hormone Output: Evidence against the Connection between Senile Hypogonadism and Somatopause
J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3255 - 3260.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. J. van der Lely, M. Tschop, M. L. Heiman, and E. Ghigo
Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin
Endocr. Rev., June 1, 2004; 25(3): 426 - 457.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Y. Bowers, R. Granda, S. Mohan, J. Kuipers, D. Baylink, and J. D. Veldhuis
Sustained Elevation of Pulsatile Growth Hormone (GH) Secretion and Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-3 (IGFBP-3), and IGFBP-5 Concentrations during 30-Day Continuous Subcutaneous Infusion of GH-Releasing Peptide-2 in Older Men and Women
J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2290 - 2300.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. Sun, P. Wang, H. Zheng, and R. G. Smith
Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor
PNAS, March 30, 2004; 101(13): 4679 - 4684.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
A. INUI, A. ASAKAWA, C. Y. BOWERS, G. MANTOVANI, A. LAVIANO, M. M. MEGUID, and M. FUJIMIYA
Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ
FASEB J, March 1, 2004; 18(3): 439 - 456.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
Y. Sun, S. Ahmed, and R. G. Smith
Deletion of Ghrelin Impairs neither Growth nor Appetite
Mol. Cell. Biol., November 15, 2003; 23(22): 7973 - 7981.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Tassone, F. Broglio, S. Destefanis, S. Rovere, A. Benso, C. Gottero, F. Prodam, R. Rossetto, C. Gauna, A. J. van der Lely, et al.
Neuroendocrine and Metabolic Effects of Acute Ghrelin Administration in Human Obesity
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5478 - 5483.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
N. M. Thompson, J. S Davies, A. Mode, P. A. Houston, and T. Wells
Pattern-Dependent Suppression of Growth Hormone (GH) Pulsatility by Ghrelin and GH-Releasing Peptide-6 in Moderately GH-Deficient Rats
Endocrinology, November 1, 2003; 144(11): 4859 - 4867.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Broglio, C. Gottero, A. Benso, F. Prodam, S. Destefanis, C. Gauna, M. Maccario, R. Deghenghi, A. J. van der Lely, and E. Ghigo
Effects of Ghrelin on the Insulin and Glycemic Responses to Glucose, Arginine, or Free Fatty Acids Load in Humans
J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4268 - 4272.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Broglio, A. Benso, C. Castiglioni, C. Gottero, F. Prodam, S. Destefanis, C. Gauna, A. J. van der Lely, R. Deghenghi, M. Bo, et al.
The Endocrine Response to Ghrelin as a Function of Gender in Humans in Young and Elderly Subjects
J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1537 - 1542.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Broglio, E. Arvat, A. Benso, C. Gottero, F. Prodam, S. Grottoli, M. Papotti, G. Muccioli, A. J. van der Lely, R. Deghenghi, et al.
Endocrine Activities of Cortistatin-14 and Its Interaction with GHRH and Ghrelin in Humans
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3783 - 3790.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. Kamegai, H. Tamura, T. Shimizu, S. Ishii, H. Sugihara, and I. Wakabayashi
Chronic Central Infusion of Ghrelin Increases Hypothalamic Neuropeptide Y and Agouti-Related Protein mRNA Levels and Body Weight in Rats
Diabetes, November 1, 2001; 50(11): 2438 - 2443.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. G. Murphy, S. Weiss, M. McClung, T. Schnitzer, K. Cerchio, J. Connor, D. Krupa, and B. J. Gertz
Effect of Alendronate and MK-677 (a Growth Hormone Secretagogue), Individually and in Combination, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women
J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1116 - 1125.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. F. Muller, J. A. Janssen, L. J. Hofland, S. W. Lamberts, M. Bidlingmaier, C. J. Strasburger, and A. J. van der Lely
Blockade of the Growth Hormone (GH) Receptor Unmasks Rapid GH-Releasing Peptide-6-Mediated Tissue-Specific Insulin Resistance
J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 590 - 593.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. Shah, W. S. Evans, C. Y. Bowers, and J. D. Veldhuis
Oral Estradiol Administration Modulates Continuous Intravenous Growth Hormone (GH)-Releasing Peptide-2-Driven GH Secretion in Postmenopausal Women
J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2649 - 2659.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
R. Nass, J. Gilrain, S. Anderson, B. Gaylinn, A. Dalkin, R. Day, M. Peruggia, and M. O. Thorner
High Plasma Growth Hormone (GH) Levels Inhibit Expression of GH Secretagogue Receptor Messenger Ribonucleic Acid Levels in the Rat Pituitary
Endocrinology, June 1, 2000; 141(6): 2084 - 2089.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
O. C. Palyha, S. D. Feighner, C. P. Tan, K. K. McKee, D. L. Hreniuk, Y.-D. Gao, K. D. Schleim, L. Yang, G. J. Morriello, R. Nargund, et al.
Ligand Activation Domain of Human Orphan Growth Hormone (GH) Secretagogue Receptor (GHS-R) Conserved from Pufferfish to Humans
Mol. Endocrinol., January 1, 2000; 14(1): 160 - 169.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Russell-Aulet, C. A. Jaffe, R. DeMott-Friberg, and A. L. Barkan
In Vivo Semiquantification of Hypothalamic Growth Hormone-Releasing Hormone (GHRH) Output in Humans: Evidence for Relative GHRH Deficiency in Aging
J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3490 - 3497.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Svensson, J.-O. Jansson, M. Ottosson, G. Johannsson, M.-R. Taskinen, O. Wiklund, and B.-A. Bengtsson
Treatment of Obese Subjects with the Oral Growth Hormone Secretagogue MK-677 Affects Serum Concentrations of Several Lipoproteins, But Not Lipoprotein(a)
J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2028 - 2033.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. Shah, W. S. Evans, C. Y. Bowers, and J. D. Veldhuis
Tripartite Neuroendocrine Activation of the Human Growth Hormone (GH) Axis in Women by Continuous 24-Hour GH-Releasing Peptide Infusion: Pulsatile, Entropic, and Nyctohemeral Mechanisms
J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2140 - 2150.
[Abstract] [Full Text]

Home page
 Physiol. Rev.Home page
E. E. Muller, V. Locatelli, and D. Cocchi
Neuroendocrine Control of Growth Hormone Secretion
Physiol Rev, April 1, 1999; 79(2): 511 - 607.
[Abstract] [Full Text] [PDF]

Home page
 ptjournalHome page
J. J Zachwieja and K. E Yarasheski
Does Growth Hormone Therapy in Conjunction With Resistance Exercise Increase Muscle Force Production and Muscle Mass in Men and Women Aged 60 Years or Older?
Physical Therapy, January 1, 1999; 79(1): 76 - 82.
[Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. Giustina and J. D. Veldhuis
Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human
Endocr. Rev., December 1, 1998; 19(6): 717 - 797.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Micic, V. Popovic, M. Doknic, D. Macut, C. Dieguez, and F. F. Casanueva
Preserved Growth Hormone (GH) Secretion in Aged and Very Old Subjects after Testing with the Combined Stimulus GH-Releasing Hormone plus GH-Releasing Hexapeptide-6
J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2569 - 2572.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. N. Roemmich, P. A. Clark, V. Mai, S. S. Berr, A. Weltman, J. D. Veldhuis, and A. D. Rogol
Alterations in Growth and Body Composition During Puberty: III. Influence of Maturation, Gender, Body Composition, Fat Distribution, Aerobic Fitness, and Energy Expenditure on Nocturnal Growth Hormone Release
J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1440 - 1447.
[Abstract] [Full Text]

Home page
 Toxicol PatholHome page
C. A. Bondy
Growth Hormone Augmentation--A New Era?
Toxicol Pathol, March 1, 1998; 26(2): 213 - 216.
[PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. Van den Berghe, F. de Zegher, R. C. Baxter, J. D. Veldhuis, P. Wouters, M. Schetz, C. Verwaest, E. Van der Vorst, P. Lauwers, R. Bouillon, et al.
Neuroendocrinology of Prolonged Critical Illness: Effects of Exogenous Thyrotropin-Releasing Hormone and Its Combination with Growth Hormone Secretagogues
J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 309 - 319.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Svensson, L. Lönn, J.-O. Jansson, G. Murphy, D. Wyss, D. Krupa, K. Cerchio, W. Polvino, B. Gertz, I. Boseaus, et al.
Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure
J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 362 - 369.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. J. Rosen and C. Conover
Growth Hormone/Insulin-Like Growth Factor-I Axis in Aging: A Summary of a National Institutes of Aging-Sponsored Symposium
J. Clin. Endocrinol. Metab., December 1, 1997; 82(12): 3919 - 3922.
[Full Text] [PDF]

Home page
 ScienceHome page
S. W. Lamberts, A. W. van den Beld, and A. van der Lely
The Endocrinology of Aging
Science, October 17, 1997; 278(5337): 419 - 424.
[Abstract] [Full Text]

Home page
 Endocr. Rev.Home page
R. G. Smith, L. H. T. Van der Ploeg, A. D. Howard, S. D. Feighner, K. Cheng, G. J. Hickey, M. J. Wyvratt Jr., M. H. Fisher, R. P. Nargund, and A. A. Patchett
Peptidomimetic Regulation of Growth Hormone Secretion
Endocr. Rev., October 1, 1997; 18(5): 621 - 645.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
I. M. Chapman, O. H. Pescovitz, G. Murphy, T. Treep, K. A. Cerchio, D. Krupa, B. Gertz, W. J. Polvino, E. H. Skiles, S. S. Pezzoli, et al.
Oral Administration of Growth Hormone (GH) Releasing Peptide-Mimetic MK-677 Stimulates the GH/Insulin-Like Growth Factor-I Axis in Selected GH-Deficient Adults
J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3455 - 3463.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
H. Zheng, A. Bailey, M.-H. Jiang, K. Honda, H. Y. Chen, M. E. Trumbauer, L. H.T. Van der Ploeg, J. M. Schaeffer, G. Leng, and R. G. Smith
Somatostatin Receptor Subtype 2 Knockout Mice Are Refractory to Growth Hormone-Negative Feedback on Arcuate Neurons
Mol. Endocrinol., October 1, 1997; 11(11): 1709 - 1717.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
R. G. Clark, G. B. Thomas, D. L. Mortensen, W. B. Won, Y. H. Ma, E. E. Tomlinson, K. M. Fairhall, and I. C. A. F. Robinson
Growth Hormone Secretagogues Stimulate the Hypothalamic-Pituitary-Adrenal Axis and Are Diabetogenic in the Zucker Diabetic Fatty Rat
Endocrinology, October 1, 1997; 138(10): 4316 - 4323.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Ghigo, E. Arvat, J. Ramunni, A. Colao, L. Gianotti, R. Deghenghi, G. Lombardi, and F. Camanni
Adrenocorticotropin- and Cortisol-Releasing Effect of Hexarelin, a Synthetic Growth Hormone-Releasing Peptide, in Normal Subjects and Patients with Cushing's Syndrome
J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2439 - 2444.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. A. Toogood, R. M. Nass, S. S. Pezzoli, P. A. O'Neill, M. O. Thorner, and S. M. Shalet
Preservation of Growth Hormone Pulsatility Despite Pituitary Pathology, Surgery, and Irradiation
J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2215 - 2221.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1996 by The Endocrine Society